CPS Technologies (CPSH) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
10 Nov, 2026Executive summary
Q3 revenue was $8.900M, up from $8.804M a year earlier; gross margin rose to 20.9% and operating income reached $357,747.
Strong demand and new orders support continued growth, while the planned move to a larger Attleboro facility is intended to expand production capacity and improve efficiency.
Financial highlights
Q3 gross profit was $1.856M versus $1.503M; net income was $346,757 versus $207,964, and diluted EPS was $0.02 versus $0.01.
9M revenue was $24.239M versus $24.388M; operating loss was $423,415 versus operating income of $542,659, and net income was $90,324 versus $407,759.
9M operating cash flow was negative $2.63M versus positive $447K, including a $4.72M inventory increase in operating cash-flow adjustments.
Q3 SG&A was $1.5M versus $1.2M YoY, including $88K of non-cash lease charges.
At September 26, cash and cash equivalents were $3.30M and marketable securities were $15.61M; accounts receivable was $4.7M and inventory was $10.32M.
Outlook and guidance
Significant volume orders from the largest semiconductor customer support deliveries into FY2027 at levels consistent with the prior-year period; management expects continued growth and higher financial results.
Approximately $10M of Attleboro build-out capital expenditure is expected in 2027; funding may come from cash, marketable securities and operating cash flow, with up to $3.2M of qualifying costs eligible for tenant-improvement reimbursement.
A partial move may begin earlier in 2027; complex production requirements could extend full build-out into H2 2027, with occupancy expected in November 2027.
Inventory is being built to support customer supply continuity through the production transition; management expects existing liquidity to cover requirements for the foreseeable future.
Latest events from CPS Technologies
- Q2 2026 revenue up to $8.3M, $9.6M raised, and margin recovery amid rising costs.CPSH
Q2 2026 - Q1 2026 revenue and margins declined, but growth and margin recovery are expected ahead.CPSH
Q1 2026 - 2026 meeting seeks approval for directors, executive pay, share increase, and auditor ratification.CPSH
Proxy filing - Annual meeting to vote on directors, executive pay, share increase, and auditor ratification.CPSH
Proxy Filing - Record revenue, margin gains, and facility expansion drive strong growth outlook.CPSH
Q4 2025 - Record revenue, margin gains, and major contracts drive expansion amid ongoing market risks.CPSH
Q3 2025 - Record Q2 2025 revenue, profitability, and strong demand drive a positive outlook.CPSH
Q2 2025 - Revenue and margins fell in Q2, but new contracts and product launches support future growth.CPSH
Q2 2024 - Record Q1 2025 revenue and profitability, with strong growth and improved margins.CPSH
Q1 2025